Selection and characterization of human melanoma lines with different liver-colonizing capacity

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Two human melanoma lines with low (HT168) and high (HT168-M1) liver metastatic capacity in immunosuppressed mice were selected in vivo from the A2058 cell line. After i.v. injection of the 2 tumor lines there was no significant difference either in the number of lung colonies or in the frequency and tissue distribution of extrapulmonary tumor deposits. These findings suggest that the selection in the spleen-liver system did not result in an overall increase in the metastatic potential of the melanoma cells, but rather that it represented an organ-preferential selection. The HT168-M1 cells did not acquire an increased growth rate in vitro or in vivo, suggesting that other phenotypic alterations are responsible for the enhanced metastatic capacity. The 2 tumor lines were characterized by similar expression of HLA-A,B,C, transferrin receptor and melanoma-associated proteoglycan antigen. HT168 contained more NGF receptor, while HLA-DR appeared only on HT168-M1 cells. This human metastasis model could be useful in studying the mechanisms of liver metastasis formation, as well as in revealing possible new targets of anti-metastatic therapy.

Original languageEnglish
Pages (from-to)456-461
Number of pages6
JournalInternational Journal of Cancer
Volume46
Issue number3
DOIs
Publication statusPublished - 1990

Fingerprint

Melanoma
Liver
Neoplasm Metastasis
Nerve Growth Factor Receptor
Neoplasms
Transferrin Receptors
HLA-A Antigens
HLA-B Antigens
HLA-DR Antigens
Tissue Distribution
Proteoglycans
Spleen
Antigens
Cell Line
Lung
Injections
Growth
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{054b01957ae1483cb99b229aa4e473b4,
title = "Selection and characterization of human melanoma lines with different liver-colonizing capacity",
abstract = "Two human melanoma lines with low (HT168) and high (HT168-M1) liver metastatic capacity in immunosuppressed mice were selected in vivo from the A2058 cell line. After i.v. injection of the 2 tumor lines there was no significant difference either in the number of lung colonies or in the frequency and tissue distribution of extrapulmonary tumor deposits. These findings suggest that the selection in the spleen-liver system did not result in an overall increase in the metastatic potential of the melanoma cells, but rather that it represented an organ-preferential selection. The HT168-M1 cells did not acquire an increased growth rate in vitro or in vivo, suggesting that other phenotypic alterations are responsible for the enhanced metastatic capacity. The 2 tumor lines were characterized by similar expression of HLA-A,B,C, transferrin receptor and melanoma-associated proteoglycan antigen. HT168 contained more NGF receptor, while HLA-DR appeared only on HT168-M1 cells. This human metastasis model could be useful in studying the mechanisms of liver metastasis formation, as well as in revealing possible new targets of anti-metastatic therapy.",
author = "A. Lad{\'a}nyi and J. T{\'i}m{\'a}r and S. Paku and G. Molnar and K. Lapis",
year = "1990",
doi = "10.1002/ijc.2910460322",
language = "English",
volume = "46",
pages = "456--461",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Selection and characterization of human melanoma lines with different liver-colonizing capacity

AU - Ladányi, A.

AU - Tímár, J.

AU - Paku, S.

AU - Molnar, G.

AU - Lapis, K.

PY - 1990

Y1 - 1990

N2 - Two human melanoma lines with low (HT168) and high (HT168-M1) liver metastatic capacity in immunosuppressed mice were selected in vivo from the A2058 cell line. After i.v. injection of the 2 tumor lines there was no significant difference either in the number of lung colonies or in the frequency and tissue distribution of extrapulmonary tumor deposits. These findings suggest that the selection in the spleen-liver system did not result in an overall increase in the metastatic potential of the melanoma cells, but rather that it represented an organ-preferential selection. The HT168-M1 cells did not acquire an increased growth rate in vitro or in vivo, suggesting that other phenotypic alterations are responsible for the enhanced metastatic capacity. The 2 tumor lines were characterized by similar expression of HLA-A,B,C, transferrin receptor and melanoma-associated proteoglycan antigen. HT168 contained more NGF receptor, while HLA-DR appeared only on HT168-M1 cells. This human metastasis model could be useful in studying the mechanisms of liver metastasis formation, as well as in revealing possible new targets of anti-metastatic therapy.

AB - Two human melanoma lines with low (HT168) and high (HT168-M1) liver metastatic capacity in immunosuppressed mice were selected in vivo from the A2058 cell line. After i.v. injection of the 2 tumor lines there was no significant difference either in the number of lung colonies or in the frequency and tissue distribution of extrapulmonary tumor deposits. These findings suggest that the selection in the spleen-liver system did not result in an overall increase in the metastatic potential of the melanoma cells, but rather that it represented an organ-preferential selection. The HT168-M1 cells did not acquire an increased growth rate in vitro or in vivo, suggesting that other phenotypic alterations are responsible for the enhanced metastatic capacity. The 2 tumor lines were characterized by similar expression of HLA-A,B,C, transferrin receptor and melanoma-associated proteoglycan antigen. HT168 contained more NGF receptor, while HLA-DR appeared only on HT168-M1 cells. This human metastasis model could be useful in studying the mechanisms of liver metastasis formation, as well as in revealing possible new targets of anti-metastatic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025033710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025033710&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910460322

DO - 10.1002/ijc.2910460322

M3 - Article

C2 - 2203689

AN - SCOPUS:0025033710

VL - 46

SP - 456

EP - 461

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -